Sample testing device and sample testing method

Abstract

The application discloses a sample detection device and a sample detection method. In the sample detection device, a pipette needle assembly is used to suck and spit the sample; a glycosylation detection module is used to perform glycosylation detection on the sample; a blood routine detection module is used to perform blood routine detection on the sample; and a control module is used to control the pipette needle assembly to collect a first sample and a second sample, so that the first sample and the second sample are temporarily stored in the pipette needle assembly at the same time; the pipette needle assembly is controlled to perform first sample separation work and second sample separation work in sequence, or the pipette needle assembly is controlled to perform the second sample separation work and the first sample separation work in sequence; and before the pipette needle assembly performs the first sample separation work, a glycosylation hemolytic agent is used to clean the pipette needle assembly. Based on the above mode, the possibility of cross contamination between blood routine detection and glycosylation detection can be reduced, and the reliability of sample detection is improved.

Description

Technical Field

[0001] This application relates to the field of sample testing technology, and in particular to sample testing devices and sample testing methods. Background Technology

[0002] In existing technologies, production lines are usually equipped with blood routine testing devices and glycated hemoglobin testing devices. Specifically, the glycated hemoglobin testing device can be a device that detects glycated hemoglobin based on high performance liquid chromatography (HPLC).

[0003] The drawback of existing technology is that, in essence, the routine blood test device and the glycated blood glucose test device on the production line are two independent operating devices. If these two independent operating devices directly share the same sample separation component to perform routine blood test and glycated blood glucose test separately, it is easy to cause cross-contamination between the sample solution or reagents used in the glycated blood glucose test and the sample solution or reagents used in the routine blood glucose test. This will affect the accuracy of at least one of the tests, making the reliability of the existing sample testing based on the combined routine blood glucose test and glycated blood glucose test relatively low. Summary of the Invention

[0004] The main technical problem addressed in this application is how to reduce the possibility of cross-contamination between routine blood tests and glycation end products (GUP) tests, thereby improving the reliability of sample testing.

[0005] To solve the above-mentioned technical problems, the first technical solution adopted in this application is: a sample detection device, comprising: a pipette assembly for aspirating and dispensing samples; a glycation detection module for performing glycation detection on the samples; a complete blood count (CBC) detection module for performing CBC detection on the samples; and a control module for: controlling the pipette assembly to collect a first sample and a second sample, so that the first sample and the second sample are simultaneously and temporarily stored in the pipette assembly; the first sample is a sample for glycation detection, and the second sample is a sample for CBC detection; controlling the pipette assembly to sequentially perform a first dispensing operation and a second dispensing operation, or sequentially performing a second dispensing operation and a first dispensing operation; the first dispensing operation and the second dispensing operation are operations of the pipette assembly dispensing the first sample and the second sample, respectively; and cleaning the pipette assembly with a glycation lysing agent before controlling the pipette assembly to perform the first dispensing operation.

[0006] The control module is also used to clean the pipette assembly with diluent after controlling the pipette assembly to perform the first sample dispensing operation.

[0007] Specifically, the control module is used to: clean the outer wall of the pipette assembly with a glycosylated hemolysin before controlling the pipette assembly to perform the first sample dispensing operation; and clean the outer wall of the pipette assembly with a diluent after controlling the pipette assembly to perform the first sample dispensing operation.

[0008] Specifically, the control module is used to: in response to the pipette assembly performing the first and second sample dispensing operations sequentially, before controlling the pipette assembly to perform the first sample dispensing operation, clean the outer wall of the pipette assembly with a glycated hemolysin; after controlling the pipette assembly to perform the first sample dispensing operation and before controlling the pipette assembly to perform the second sample dispensing operation, clean the outer wall of the pipette assembly with a diluent; and after the pipette assembly performs the second sample dispensing operation, clean both the inner and outer walls of the pipette assembly with a diluent.

[0009] Specifically, the control module is used to: in response to the pipette assembly performing the second and first sample dispensing operations sequentially, after controlling the pipette assembly to perform the second sample dispensing operation and before controlling the pipette assembly to perform the first sample dispensing operation, clean the outer wall of the pipette assembly with a glycated hemolysin and clean both the inner and outer walls of the pipette assembly with a diluent after the pipette assembly performs the first sample dispensing operation.

[0010] The control module is further configured to perform at least one of the following operations to clean the outer wall of the pipette assembly: First, the sample detection device further includes a reaction cell module. The control module controls the movement of the pipette assembly so that the needle of the pipette assembly is below the surface of the glycated hemolysin in the reaction cell module, the distance between the needle of the pipette assembly below the surface of the glycated hemolysin and the surface of the glycated hemolysin is a first distance; the control module is also configured to control the movement of the pipette assembly so that the pipette assembly dispenses a first sample into the reaction cell module, so that the needle of the pipette assembly remains below the surface of the first sample in the reaction cell module during the dispensing of the first sample, the pipette assembly below the surface of the first sample... The distance between the needle tip of the needle assembly and the liquid surface of the first sample is the second distance; the first distance is greater than the second distance; the second type: the sample detection device also includes a cleaning swab, which is used to clean the outer wall of the pipette assembly. The cleaning swab is connected to the common port of the first three-way valve. The first branch port of the first three-way valve is used to receive the glycated hemolysin, and the second branch port of the first three-way valve is used to receive the diluent; the control module is used to control the common port of the first three-way valve to connect with its first branch port, so as to control the cleaning swab to clean the outer wall of the pipette assembly with the glycated hemolysin. The control module is also used to control the common port of the first three-way valve to connect with its second branch port, so as to control the cleaning swab to clean the outer wall of the pipette assembly with the diluent.

[0011] The control module is also used to perform at least one of the following operations: First, controlling the pipette assembly to collect a third sample and perform a third sample dispensing operation, wherein the third sample dispensing operation is a dispensing operation to dispense the third sample for glycation detection, and the third sample is a hemolyzed sample; before and after performing the third sample dispensing operation, the inner wall of the pipette assembly is cleaned with a glycation lysing agent; when cleaning the inner wall of the pipette assembly with the glycation lysing agent, the volume of glycation lysing agent aspirated by the pipette assembly is a first volume; when the pipette assembly collects the third sample... In this case, the volume of the third sample aspirated by the pipette assembly is the second volume; the first volume is larger than the second volume; the second method: the pipette assembly is connected to the common port of the second three-way valve, the first port of the second three-way valve is used to receive the glycated hemolysin, and the second port of the second three-way valve is used to receive the diluent; the control module is used to control the common port of the second three-way valve to connect with its first port, and to use the glycated hemolysin to clean the inner wall of the pipette assembly; the control module is also used to control the common port of the second three-way valve to connect with its second port, and to use the diluent to clean the inner wall of the pipette assembly.

[0012] The sample testing device also includes a reaction chamber module; the reaction chamber module includes a common reaction chamber, and the control module is used to control the pipette assembly to perform one of the first and second sample dispensing operations in the common reaction chamber and to perform the corresponding detection; the control module is also used to control the pipette assembly to perform the other of the first and second sample dispensing operations in the common reaction chamber and to perform the corresponding detection; the time period of glycated glucose testing overlaps at least partially with the time period of routine blood tests.

[0013] The sample testing device further includes a reaction chamber module; the reaction chamber module includes a first reaction chamber and a second reaction chamber; the control module is used to control the pipette assembly to perform a first sample dispensing operation in the first reaction chamber and perform the corresponding glycation detection; the control module is also used to control the pipette assembly to perform a second sample dispensing operation in the second reaction chamber and perform the corresponding blood routine test; the time period of glycation detection and the time period of blood routine test at least partially overlap.

[0014] To solve the above-mentioned technical problems, the second technical solution adopted in this application is: a sample detection method, the sample detection method comprising: controlling a pipette assembly to collect a first sample and a second sample, so as to temporarily store the first sample and the second sample simultaneously in the pipette assembly; the first sample is a sample for glycation detection, and the second sample is a sample for blood routine testing; controlling the pipette assembly to sequentially perform a first sample dispensing operation and a second sample dispensing operation, or sequentially performing a second sample dispensing operation and a first sample dispensing operation; the first sample dispensing operation and the second sample dispensing operation are respectively operations of the pipette assembly dispensing the first sample and the second sample; before controlling the pipette assembly to perform the first sample dispensing operation, the pipette assembly is cleaned with a glycation hemolysin.

[0015] The beneficial effects of this application are as follows: Unlike existing technologies, the sample testing device in this application includes a pipette assembly, a glycation end product (GAP) detection module, a complete blood count (CBC) detection module, and a control module. The control module is used to: control the pipette assembly to collect a first sample and a second sample, so that the first sample and the second sample are simultaneously and temporarily stored within the pipette assembly; wherein the first sample is for GLP detection, and the second sample is for CBC detection; control the pipette assembly to sequentially perform a first dispensing operation and a second dispensing operation, or sequentially perform a second dispensing operation and a first dispensing operation; wherein the first dispensing operation and the second dispensing operation are respectively operations of the pipette assembly dispensing the first sample and the second sample; before controlling the pipette assembly to perform the first dispensing operation, the pipette assembly is cleaned with a GAP lysing agent. Based on the above method, in the same device, the pipette assembly can be controlled to collect a first sample for glycation end product (GEP) testing and a second sample for complete blood count (CBC) testing, respectively. The first and second samples are then sequentially separated. Before the first separation, the pipette assembly is cleaned with a glycation dissolving agent to remove any residual diluent, reducing or eliminating contamination of the first sample. This cleaning step, whether the first separation is performed before or after the second separation, reduces the possibility of high-strength ions from the diluent being carried into the first sample for GEP testing, thus affecting the accuracy of the test. In other words, even when using the same pipette assembly to aspirate and dispense the first and second samples, both GEP and CBC testing can maintain sufficiently high accuracy. This minimizes the possibility of cross-contamination between GEP and GEP testing when performing combined testing in the same device, thereby improving the reliability of sample testing. Attached Figure Description

[0016] To more clearly illustrate the technical solutions in the embodiments of the present invention, the accompanying drawings used in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0017] Figure 1 This is a schematic diagram of the structure of one embodiment of the sample detection device of this application;

[0018] Figure 2 This is a schematic diagram of another embodiment of the sample detection device of this application;

[0019] Figure 3 This is a schematic diagram of the structure of another embodiment of the sample detection device of this application;

[0020] Figure 4 This is a flowchart illustrating an embodiment of the first and second sampling operations performed sequentially in this application;

[0021] Figure 5 This is a flowchart illustrating an embodiment of the sequential execution of the second and first sampling operations in this application;

[0022] Figure 6 yes Figure 4 A flowchart illustrating an embodiment of steps A2-A3;

[0023] Figure 7 This is a schematic diagram of one embodiment of the pipette assembly, cleaning swab, and first three-way valve of this application;

[0024] Figure 8 This is a schematic diagram of the structure of one embodiment of the pipette assembly of this application;

[0025] Figure 9 This is a schematic diagram of an embodiment of the pipette assembly and the second three-way valve of this application;

[0026] Figure 10 This is a flowchart illustrating an embodiment of the sample detection method of this application.

[0027] Reference numerals: pipette assembly 11, glycation end product (GA) detection module 12, complete blood count (CBC) detection module 13, control module 14, cleaning swab 15, first three-way valve 16, second three-way valve 17, reaction chamber module 18, common reaction chamber 181, first reaction chamber 182, second reaction chamber 183. Detailed Implementation

[0028] The present application will now be described in further detail with reference to the accompanying drawings and embodiments. It should be particularly noted that the following embodiments are for illustrative purposes only and do not limit the scope of the application. Similarly, the following embodiments are only some, not all, embodiments of the present application, and all other embodiments obtained by those skilled in the art without inventive effort are within the scope of protection of the present application.

[0029] In this document, the term "embodiment" means that a particular feature, structure, or characteristic described in connection with an embodiment may be included in at least one embodiment of this application. The appearance of this phrase in various places throughout the specification does not necessarily refer to the same embodiment, nor is it a mutually exclusive, independent, or alternative embodiment. It will be explicitly and implicitly understood by those skilled in the art that the embodiments described herein can be combined with other embodiments.

[0030] In the description of this application, it should be noted that, unless otherwise expressly specified and limited, the terms "installation," "setting," "connection," and "linking" should be interpreted broadly. For example, they can refer to a fixed connection, a detachable connection, or an integral connection; they can refer to a mechanical connection or an electrical connection; they can refer to a direct connection or a connection through an intermediate medium. Those skilled in the art will understand the specific meanings of the above terms within the context of this application.

[0031] This application first proposes a sample detection device, see [link to previous document]. Figure 1 , Figure 1 This is a schematic diagram of the structure of one embodiment of the sample detection device of this application, as shown below. Figure 1 As shown, the sample testing device includes a pipette assembly 11, a glycation detection module 12, a blood routine detection module 13, and a control module 14.

[0032] Among them, see Figure 2 and Figure 3 , Figure 2 This is a schematic diagram of another embodiment of the sample detection device of this application. Figure 3 This is a schematic diagram of another embodiment of the sample detection device of this application.

[0033] like Figure 2 and Figure 3 As shown, the sample detection device may also be equipped with a reaction cell module 18 and a saccharification detection module 12, which may be equipped with an elution component and a detection component. The reaction cell module 18 is used to receive the inlet liquid (sample and related reagents) and the outlet liquid (prepared sample or waste liquid). The elution component includes a high-pressure pump, a six-way valve and a chromatography column connected to each other. The elution component is used to perform gradient elution on the prepared sample output from the reaction cell module to achieve component separation. The detection component detects the component-separated sample to obtain the saccharification detection result.

[0034] The liquid path support assembly provides the power for liquid delivery. It is connected to the pipette assembly 11, the complete blood count (CBC) testing module 13, and the glycated glucose (GG) testing module 12. The control module 14 is also connected to these components. The control module 14 can control the pipette assembly to deliver the collected sample to the reaction chamber of the GG testing module 12, preparing the sample required for CBC testing. This sample is then delivered to the CBC testing module 13 to obtain the CBC test results. Furthermore, the control module 14 can also control the pipette assembly 11 to deliver the collected sample to the reaction chamber of the GG testing module 12, preparing the sample required for GG testing. This sample is then sequentially delivered to the elution assembly and the detection assembly for appropriate processing, yielding the GG test results.

[0035] In addition, the sample testing device center can also integrate erythrocyte sedimentation rate (ESR) testing devices, specific protein testing devices, and other types of testing devices to achieve the integration of more types of testing equipment, which is not limited here.

[0036] The pipette assembly 11 is used for sample aspiration and dispensing. Specifically, the pipette assembly 11 refers to the device in the sampling module used for liquid aspiration and dispensing. The pipette assembly 11 can collect samples from corresponding locations (such as collecting samples by puncturing a test tube) and dispense samples from corresponding locations (such as delivering samples to corresponding reaction cells for the preparation of sample solutions for glycation and routine blood tests, respectively) by moving in the horizontal and / or vertical directions.

[0037] The glycation detection module 12 is used to perform glycation detection on the sample. Specifically, the glycation detection module 12 is used to detect glycated hemoglobin in the corresponding sample and obtain the detection results.

[0038] The routine blood test module 13 is used to perform routine blood tests on samples. Specifically, the routine blood test module 13 is used to perform routine blood tests on the corresponding samples and obtain the test results.

[0039] Control module 14 is used for:

[0040] The pipette assembly 11 is controlled to collect a first sample and a second sample, so that the first sample and the second sample are simultaneously and temporarily stored in the pipette assembly 11. The first sample is used for glycation end product (GA) testing, and the second sample is used for complete blood count (CBC) testing.

[0041] The pipette assembly 11 is controlled to perform a first sample dispensing operation and a second sample dispensing operation sequentially, or to perform a second sample dispensing operation and a first sample dispensing operation sequentially. The first sample dispensing operation is the operation of the pipette assembly 11 dispensing a first sample, and the second sample dispensing operation is the operation of the pipette assembly 11 dispensing a second sample.

[0042] Before controlling the pipette assembly 11 to perform the first sample dispensing operation, the pipette assembly 11 is cleaned with a glycosylation agent.

[0043] Specifically, it should be noted that in the sample testing device mentioned in this application, routine blood tests and glycated blood tests can be simultaneous tests involving different parameters and different methodologies, or tests that partially overlap in time. Therefore, care should be taken to avoid mutual interference between the two testing processes.

[0044] The methodology used for glycation end product (GAP) detection is ion exchange chromatography based on ion exchange columns. Ion exchange columns, which are used to elute different components, are highly sensitive to the ionic strength of the sample passing through them. However, the reagents involved in routine blood tests (such as diluents) have high ionic strength, which can easily interfere with the detection of ion exchange columns. Therefore, it is necessary to avoid situations where ions from reagents involved in routine blood tests are introduced into the GLP detection process and cause interference.

[0045] Therefore, by cleaning the pipette assembly 11 with a glycated hemolysin before performing the first sampling operation, even if a second sampling operation has been performed before the first sampling operation, the glycated hemolysin can be used to clean any residual diluent. In other words, this minimizes the possibility that the diluent used and left over from the second sampling operation may contaminate the sample from the first sampling operation, thereby negatively affecting the subsequent glycated test corresponding to the first sampling operation. This reduces the possibility of cross-contamination between glycated test and routine blood test, and improves the reliability of sample testing.

[0046] In a further example, before controlling the pipette assembly 11 to perform the first dispensing operation, the pipette assembly 11 is cleaned with a glycated hemolysin, which may further include:

[0047] Before controlling the pipette assembly 11 to perform the first sample dispensing operation, the pipette assembly 11 is cleaned with a glycosylation agent.

[0048] After the pipette assembly 11 performs the first sample dispensing operation, the pipette assembly 11 is cleaned with diluent.

[0049] Specifically, the reagents involved in glycation testing (such as glycation lysing agents) may also interfere with routine blood tests. Therefore, corresponding measures should be taken to minimize the interference of reagents involved in glycation testing with routine blood tests. That is, by using a diluent to clean the glycation lysing agents that may remain in the first blood separation operation, the possibility of glycation lysing agents having a negative impact on the routine blood tests corresponding to the second sample separation operation can be reduced. This further reduces the possibility of cross-contamination between glycation testing and routine blood tests and improves the reliability of sample testing.

[0050] It should be noted that the pipette assembly 11 may specifically include a pipette and a power source for the pipette. The power source can provide suction or thrust to the pipette to achieve the aspiration and expulsion of liquid through the pipette. The cleaning of the pipette mentioned above may specifically refer to the cleaning of the outer wall and / or inner wall of the pipette.

[0051] In practice, before controlling the pipette assembly 11 to perform the first sample dispensing operation, the pipette assembly 11 is cleaned with a glycated hemolysin, and after controlling the pipette assembly 11 to perform the first sample dispensing operation, the pipette assembly 11 is cleaned with a diluent. Specifically, this may include:

[0052] Before the pipette assembly 11 performs the first sample dispensing operation, the outer wall of the pipette assembly 11 is cleaned with a glycosylation agent.

[0053] After the pipette assembly 11 performs the first sample dispensing operation, the outer wall of the pipette assembly 11 is cleaned with a diluent.

[0054] Specifically, based on the above theory and the steps executed by the control module 14, in one example, during the process of glycation detection and routine blood test in the sample detection device, the pipette assembly 11 can be controlled to sequentially aspirate the first sample and the second sample. Since the second sample is aspirated later, a second sample separation operation can be performed on the second sample first. Then, before performing the first sample separation operation, the outer wall of the pipette assembly 11 is cleaned with a glycation lysing agent. Then, the first sample separation operation is performed on the first sample. Finally, after performing the first sample separation operation, the inner and outer walls of the pipette assembly 11 are cleaned with a diluent.

[0055] In another example, during the glycated blood glucose test and routine blood test in the sample testing device, the pipette assembly 11 can be controlled to sequentially aspirate the second sample and the first sample. Since the first sample is aspirated later, the outer wall of the pipette assembly 11 can be cleaned with a glycated hemolysin before the first sample separation operation, and then the first sample separation operation for the first sample can be performed. After the first sample separation operation, the outer wall of the pipette assembly 11 can be cleaned with a diluent, and then the second sample separation operation for the second sample can be performed. Finally, the inner and outer walls of the pipette assembly 11 can be cleaned with a diluent.

[0056] It is evident that, regardless of the order in which the first and second sampling operations are performed in any example, as long as the steps of cleaning the outer wall of the pipette assembly 11 with a glycated hemolysin before controlling the pipette assembly 11 to perform the first sampling operation, and cleaning the outer wall of the pipette assembly 11 with a diluent after controlling the pipette assembly 11 to perform the first sampling operation, are performed, the outer wall of the pipette assembly 11 shared by the two sampling operations can be cleaned with a glycated hemolysin that will not cause excessive interference to the glycated detection before each first sampling operation. This achieves the goal of minimizing the interference of the reagents involved in the blood routine test corresponding to the second sampling operation with the glycated detection corresponding to the first sampling operation.

[0057] This also allows the outer wall of the pipette assembly 11, which is shared by both sampling operations, to be cleaned with a diluent that will not cause excessive interference to the routine blood count before each second sampling operation following the first. When the second sampling operation is performed before the first, since the inner and outer walls of the pipette assembly 11 are usually cleaned with a diluent after each sampling operation, it is usually not necessary to clean it again and the pipette assembly 11 can be directly controlled to perform the second sampling operation. This also helps to minimize the possibility that the reagents involved in the glycated glucose assay corresponding to the first sampling operation will interfere with the routine blood count corresponding to the second sampling operation.

[0058] It should also be noted that the above-mentioned glycation assays that can be performed simultaneously with routine blood tests usually refer to the situation where glycation assays and routine blood tests are performed separately for whole blood samples. If glycation assays are required for hemolyzed samples, the outer wall of the pipette assembly 11 needs to be cleaned with a glycation lysing agent before the pipette assembly 11 collects the hemolyzed sample. After the pipette assembly 11 delivers the hemolyzed sample to the reaction cell module, the inner and outer walls of the pipette assembly 11 need to be cleaned with a glycation lysing agent. That is, during this process, the pipette assembly 11 will only collect hemolyzed samples and will only be used for glycation assays. This avoids interference with other types of assays caused by glycation assays for hemolyzed samples, thereby improving the accuracy of glycation assays for hemolyzed samples and preventing glycation assays from interfering with other types of assays, thus improving the reliability of the sample testing device.

[0059] If, after testing hemolyzed samples, it is necessary to begin collecting and separating samples for routine blood tests, then the inner and outer walls of the pipette assembly 11 still need to be cleaned with diluent.

[0060] Unlike existing technologies, the sample testing device in this application includes a pipette assembly, a glycation end product (GAP) detection module, a complete blood count (CBC) detection module, and a control module. The control module is used to: control the pipette assembly to collect a first sample and a second sample, so that the first sample and the second sample are simultaneously and temporarily stored in the pipette assembly; wherein the first sample is for GLP detection and the second sample is for CBC detection; control the pipette assembly to perform a first dispensing operation and a second dispensing operation sequentially, or to perform a second dispensing operation and a first dispensing operation sequentially; wherein the first dispensing operation and the second dispensing operation are respectively the operations of the pipette assembly dispensing the first sample and the second sample; before controlling the pipette assembly to perform the first dispensing operation, the pipette assembly is cleaned with a GA lysing agent. Based on the above method, in the same device, the pipette assembly can be controlled to collect a first sample for glycation end product (GEP) testing and a second sample for complete blood count (CBC) testing, respectively. The first and second samples are then sequentially separated. Before the first separation, the pipette assembly is cleaned with a glycation dissolving agent to remove any residual diluent, reducing or eliminating contamination of the first sample. This cleaning step, whether the first separation is performed before or after the second separation, reduces the possibility of high-strength ions from the diluent being carried into the first sample for GEP testing, thus affecting the accuracy of the test. In other words, even when using the same pipette assembly to aspirate and dispense the first and second samples, both GEP and CBC testing can maintain sufficiently high accuracy. This minimizes the possibility of cross-contamination between GEP and GEP testing when performing combined testing in the same device, thereby improving the reliability of sample testing.

[0061] In one embodiment, the control module 14 is specifically used for:

[0062] In response to the pipette assembly 11 sequentially performing the first and second sample dispensing operations, the outer wall of the pipette assembly 11 is cleaned with a glycated hemolysin before the first sample dispensing operation. After the first sample dispensing operation and before the second sample dispensing operation, the outer wall of the pipette assembly 11 is cleaned with a diluent. After the second sample dispensing operation, both the inner and outer walls of the pipette assembly 11 are cleaned with a diluent.

[0063] Specifically, see Figure 4 , Figure 4 This is a flowchart illustrating an embodiment of the sequential first and second sampling operations of this application.

[0064] In one example, such as Figure 4 As shown, the process of this embodiment is as follows:

[0065] A1, control the pipette assembly 11 to puncture the corresponding sample tubes and aspirate the second sample and the first sample respectively.

[0066] A2. Place the pipette assembly 11 into a container (such as a reaction cell module) containing a glycated hemolysin for cleaning.

[0067] A3, control the pipette assembly 11 to perform subsurface sampling in the reaction cell module to achieve the first sample separation and complete the first sampling operation.

[0068] A4. The outer wall of the pipette assembly 11 is cleaned using a diluent, either by a cleaning swab or other means.

[0069] A5 controls the pipette assembly 11 to perform subsurface sampling in the reaction cell module to achieve the second sample separation and complete the second sampling operation.

[0070] A6. Using a cleaning swab or other methods, the outer wall of the pipette assembly 11 is cleaned with a diluent, and the inner wall of the pipette assembly 11 is cleaned with a diluent by aspiration or dispensing of the diluent. Thus, the first and second sample dispensing operations are completed.

[0071] The above is just one example. The first and second sampling operations can be performed in other ways, which are not limited here.

[0072] During the glycated blood glucose test and routine blood test, if the pipette assembly 11 first aspirates the second sample and then the first sample, the first sample needs to be separated first and then the second sample needs to be separated because the first sample is closer to the needle opening than the second sample.

[0073] At this time, before the pipette assembly 11 performs the first sample dispensing operation, the outer wall of the pipette assembly 11 can be cleaned with a saccharification and hemolysis agent to reduce the possibility that residual liquid (such as diluent) on the outer wall of the pipette assembly 11 may interfere with the saccharification detection. Then, the first sample dispensing operation and the corresponding saccharification detection steps are performed in a reaction cell module.

[0074] The pipette assembly 11 can be controlled to perform the first sample dispensing operation and before performing the second sample dispensing operation. The outer wall of the pipette assembly 11 can be cleaned with diluent to reduce the possibility that residual liquid (such as glycated hemolysin) on the outer wall of the pipette assembly 11 may interfere with the blood routine test. Subsequently, the second sample dispensing operation and the corresponding blood routine test steps can be performed in the same reaction cell module after the idle period or in another reaction cell module. After the second sample dispensing operation, the inner and outer walls of the pipette assembly 11 can be cleaned with diluent.

[0075] After obtaining the results of glycated glucose and routine blood tests, the glycated glucose and routine blood tests are combined to improve the efficiency of sample testing while minimizing interference between the two tests.

[0076] Furthermore, since diluents can significantly affect glycation assays, such as dilution of the first sample causing severe distortion of the glycation assay results, the method of first drawing in the second sample and then the first sample allows most of the initial residual diluent on the inner wall of the pipette assembly 11 to be incorporated into the second sample. The dilution of the second sample is less likely to interfere with the results of the complete blood count, thus effectively improving the accuracy of simultaneous glycation assays and complete blood counts.

[0077] In one embodiment, the control module 14 is specifically used for:

[0078] In response to the pipette assembly 11 sequentially performing the second and first sample dispensing operations, after controlling the pipette assembly 11 to perform the second sample dispensing operation and before controlling the pipette assembly 11 to perform the first sample dispensing operation, the outer wall of the pipette assembly 11 is cleaned with a glycated hemolysin; and after the pipette assembly 11 performs the first sample dispensing operation, both the inner and outer walls of the pipette assembly 11 are cleaned with a diluent.

[0079] Specifically, see Figure 5 , Figure 5 This is a flowchart illustrating an embodiment of the sequential second and first sampling operations of this application.

[0080] In one example, such as Figure 5 As shown, the process of this embodiment is as follows:

[0081] B1, control the pipette assembly 11 to puncture the corresponding sample tubes and aspirate the first and second samples respectively.

[0082] B2, control the pipette assembly 11 to perform subsurface sampling in the reaction cell module to achieve the second sample separation and complete the second sampling operation.

[0083] B3. Place the pipette assembly 11 into a container (such as a reaction cell module) containing a glycated hemolysin for cleaning.

[0084] B4, control the pipette assembly 11 to perform subsurface sampling in the reaction cell module to achieve the first sample separation and complete the first sampling operation.

[0085] B5. Using a cleaning swab or other methods, the outer wall of the pipette assembly 11 is cleaned with a diluent, and using a suction or discharge diluent or other methods, the inner wall of the pipette assembly 11 is cleaned with a diluent. Thus, the first and second sample dispensing operations are completed.

[0086] In another example, based on the previous example, before performing step B1, an additional step can be added: control the pipette assembly 11 to draw in glycated hemolysin to clean the tubing through which the first sample will pass, thereby reducing the possibility that any residual diluent in the tubing may negatively affect the first sample required for glycated detection and improving the accuracy of sample detection.

[0087] Similarly, by inhaling the first sample first and then the second sample's B1-B5, combined with the above-mentioned additional steps, the pre-inhaled glycated hemolysin residue on the inner wall of the tubing can be cleaned or dissolved by the first sample. This can reduce the possibility that the residual glycated hemolysin may affect the second sample required for blood routine testing, and further improve the accuracy of sample testing.

[0088] The above are just two examples. Other methods can be used to perform the second and first sampling operations in sequence, which are not limited here.

[0089] During the glycated blood glucose test and routine blood test, if the pipette assembly 11 first aspirates the first sample and then the second sample, the second sample needs to be separated first because the second sample is closer to the needle opening than the first sample.

[0090] At this time, since the diluent that may remain on the outer wall of the pipette assembly 11 will not cause too much interference to the blood routine test, the pipette assembly 11 can be directly controlled to perform the second sample dispensing operation and the relevant steps of the blood routine test without cleaning the outer wall of the pipette assembly 11.

[0091] The pipette assembly 11 can be controlled to perform the second sample dispensing operation and before performing the first sample dispensing operation. The outer wall of the pipette assembly 11 can be cleaned with a glycation lysing agent to reduce the possibility that residual liquid (such as diluent) on the outer wall of the pipette assembly 11 will interfere with the glycation detection. Subsequently, the first sample dispensing operation and the relevant steps of the blood routine test can be continued in the same reaction cell module after the idle period, or in another reaction cell module. After the first sample dispensing operation, the inner and outer walls of the pipette assembly 11 can be cleaned with diluent.

[0092] After obtaining the results of glycated glucose and routine blood tests, the glycated glucose and routine blood tests are combined to improve the efficiency of sample testing while minimizing interference between the two tests.

[0093] In addition, since the inner and outer walls of the pipette assembly 11 are cleaned with diluent after each joint inspection, if the second sampling operation is performed first and then the first sampling operation is performed, cleaning is not required before the second sampling operation, which reduces the amount of diluent used and lowers the cleaning cost.

[0094] In one embodiment, such as Figure 2 and Figure 3 As shown, the sample detection device also includes a reaction cell module 18.

[0095] Control module 14 can be used for:

[0096] The pipette assembly 11 is controlled to move so that the tip of the pipette assembly 11 is below the surface of the glycated hemolysin in the reaction cell module 18. The distance between the tip of the pipette assembly 11 below the surface of the glycated hemolysin and the surface of the glycated hemolysin is the first distance.

[0097] Control module 14 may also be used to include:

[0098] The pipette assembly 11 is controlled to move so that it dispenses the first sample into the reaction cell module 18, and the tip of the pipette assembly 11 remains below the liquid surface of the first sample in the reaction cell module 18 during the dispensing of the first sample. The distance between the tip of the pipette assembly 11 below the liquid surface of the first sample and the liquid surface of the first sample is the second distance.

[0099] The first distance is greater than the second distance.

[0100] Specifically, in one example, see Figure 6 , Figure 6 yes Figure 4 A flowchart illustrating an embodiment of steps A2-A3 is shown below. Figure 6As shown in A2, the pipette assembly 11 can be placed into a container (such as reaction cell module 18) containing glycated hemolysin and cleaned by swinging it up and down or left and right. At this time, the first distance is S1.

[0101] A3, the controllable pipette assembly 11 can perform subsurface sampling in the reaction cell module 18 to achieve the sampling of the first sample and complete the first sampling operation. At this time, the second distance is S2.

[0102] By making the first distance S1 greater than the second distance S2, the liquid remaining on the outer wall of the pipette assembly 11, which is below the liquid surface during the first sample dispensing operation, can be pre-washed away by the glycation dissolving agent, thereby reducing the possibility of interference with glycation detection.

[0103] The above examples use Figure 4 The explanation will take steps A2-A3 as an example, and can also be replaced with... Figure 5 The explanations in B3-B4 are provided below and will not be repeated here.

[0104] In one embodiment, see Figure 7 , Figure 7 This is a schematic diagram of one embodiment of the pipette assembly, cleaning swab, and first three-way valve of this application, as shown below. Figure 7 As shown, the sample testing device also includes a cleaning swab 15, which is used to clean the outer wall of the pipette assembly 11. The cleaning swab 15 is connected to the common port of the first three-way valve 16. The first branch port of the first three-way valve 16 is used to receive the glycated hemolysin, and the second branch port of the first three-way valve 16 is used to receive the diluent.

[0105] The control module 14 can be used to: control the common port of the first three-way valve 16 to connect with its first branch port, and control the cleaning swab 15 to clean the outer wall of the pipette assembly 11 with a glycosylated hemolysin.

[0106] The control module 14 can also be used to: control the common port of the first three-way valve 16 to connect with its second branch port, and control the cleaning swab 15 to clean the outer wall of the pipette assembly 11 with diluent.

[0107] Specifically, it should be noted that the first three-way valve 16 is a three-way valve. The three-way valve mentioned in this application can specifically refer to a channel switching device with at least a three-way function. It can be a three-way valve or a device that uses a three-way function but can have a greater number of channel switching capabilities, such as a four-way valve, a five-way valve, or other number of valves. No limitation is made here.

[0108] The cleaning swab 15 is fitted outside the pipette assembly 11 and can be used to clean the outer wall of the pipette assembly 11. When the common port of the first three-way valve 16 is connected to its first branch port, the outer wall of the pipette assembly 11 can be cleaned with a glycated hemolysin. When the common port of the first three-way valve 16 is connected to its second branch port, the outer wall of the pipette assembly 11 can be cleaned with a diluent. This allows for the use of either the glycated hemolysin or the diluent to clean the outer wall of the pipette assembly 11 under any circumstances, thus improving the flexibility of the sample testing device.

[0109] In one embodiment, the control module 14 is used to:

[0110] The control pipette assembly 11 collects a third sample and performs a third sample separation operation. The third sample separation operation is the separation operation of dispensing the third sample for glycation detection. The third sample is a hemolyzed sample.

[0111] Before and after the third sample division, the inner wall of the pipette assembly 11 was cleaned with a glycosylation agent.

[0112] When the inner wall of the pipette assembly 11 is cleaned with a glycated hemolysin, the volume of the glycated hemolysin aspirated by the pipette assembly 11 is the first volume.

[0113] When the pipette assembly 11 collects the third sample, the volume of the third sample aspirated by the pipette assembly 11 is the second volume.

[0114] The first volume is greater than the second volume.

[0115] Specifically, see Figure 8 , Figure 8 This is a schematic diagram of the structure of one embodiment of the pipette assembly of this application, as shown below. Figure 8 As shown, the syringe connected to the pipette assembly 11 can be used to output diluent through the pipette assembly 11 to clean the inner wall of the pipette assembly 11. In this case, when cleaning the inner wall of the pipette assembly 11 with glycated hemolysin, the pipette assembly 11 can be controlled to draw in a first volume of glycated hemolysin. By making this first volume larger than the second volume of the subsequently dripped third sample, the diluent remaining on the inner wall of the pipette assembly 11 in contact with the third sample can be washed away by the first volume of glycated hemolysin as much as possible, thereby reducing the possibility of the diluent interfering with the glycated detection of the third sample and further improving the accuracy of sample detection.

[0116] In one embodiment, see Figure 9 , Figure 9 This is a schematic diagram of an embodiment of the pipette assembly and the second three-way valve of this application, as shown below. Figure 9As shown, the pipette assembly 11 is connected to the common port of the second three-way valve 17. The first port of the second three-way valve 17 is used to receive the glycated hemolysin, and the second port of the second three-way valve 17 is used to receive the diluent.

[0117] Control module 14 can be used for:

[0118] The common port of the second three-way valve 17 is connected to its first branch port, and the inner wall of the pipette assembly 11 is cleaned with a glycosylated hemolysin.

[0119] Control module 14 can also be used for:

[0120] The common port of the second three-way valve 17 is connected to its second branch port, and the inner wall of the pipette assembly 11 is cleaned with diluent.

[0121] Specifically, it should be noted that the second three-way valve 17 is a three-way valve. The three-way valve mentioned in this application can specifically refer to a channel switching device with at least a three-way function. It can be a three-way valve or a device that uses a three-way function but can have a maximum number of channel switching capabilities, such as a four-way valve, a five-way valve, or other number of valves. No limitation is made here.

[0122] When the common port of the second three-way valve 17 is connected to its first branch port, the inner wall of the pipette assembly 11 can be cleaned with a glycated hemolysin. Alternatively, when the common port of the second three-way valve 17 is connected to its second branch port, the inner wall of the pipette assembly 11 can be cleaned with a diluent. This allows for the use of either the glycated hemolysin or the diluent to clean the inner wall of the pipette assembly 11 under any circumstances, thus improving the flexibility of the sample testing device.

[0123] In one embodiment, the sample detection device further includes a reaction cell module 18, which includes a common reaction cell 181.

[0124] Control module 14 can be used for:

[0125] The pipette assembly 11 is controlled to perform one of the first and second sample dispensing operations in the common reaction tank 181, and the corresponding saccharification detection is performed.

[0126] The control module 14 can also be used to control the pipette assembly 11 to perform another operation in the first and second sample dispensing operations in the common reaction cell 181, and to perform corresponding blood routine tests.

[0127] The time period for glycation end product (GHEP) testing overlaps at least partially with that for routine blood tests.

[0128] Specifically, such as Figure 2As shown, when both the first and second samples are whole blood samples, the first and second sample separation operations can be performed sequentially in the same reaction pool (i.e., common reaction pool 181) in the reaction pool module 18. Combined with the relevant cleaning steps required before and after the first sample separation operation mentioned in the technical solution of this application, the possibility of mutual interference between glycated glucose detection and routine blood tests can be reduced when the same reaction pool is shared, so as to realize the joint detection of glycated glucose detection and routine blood tests and improve the efficiency of sample detection.

[0129] Furthermore, the tests performed after completing one of the first and second sampling operations can overlap in time with the tests performed after completing the other of the first and second sampling operations. That is, both routine blood tests and glycated blood glucose tests can begin after their respective sampling operations are completed. These two tests can run in parallel without interfering with each other during testing. By allowing the routine blood tests and glycated blood glucose tests to overlap in time, the overall efficiency of sample testing can also be improved.

[0130] In one embodiment, the sample detection device further includes a reaction cell module 18, which includes a first reaction cell 182 and a second reaction cell 183.

[0131] Control module 14 can be used for:

[0132] The pipette assembly 11 is controlled to perform one of the first and second sample dispensing operations in the first reaction chamber 182, and to perform the corresponding saccharification detection.

[0133] Control module 14 can also be used for:

[0134] The pipette assembly 11 is controlled to perform another operation in the first and second sample dispensing operations in the second reaction chamber 183, and to perform the corresponding blood routine test.

[0135] The time period for glycation end product (GHEP) testing overlaps at least partially with that for routine blood tests.

[0136] Specifically, such as Figure 3 As shown, when both the first and second samples are whole blood samples, the first and second sample separation operations can be performed in different reaction chambers in the reaction chamber module 18. Combined with the relevant cleaning steps required before and after the first sample separation operation mentioned in the technical solution of this application, the possibility of mutual interference between glycation detection and routine blood test can be further reduced. Furthermore, since the time periods of the first and second sample separation operations can at least partially overlap, the total sample testing time is shorter, thereby realizing the joint detection of glycation detection and routine blood test and improving the efficiency of sample testing.

[0137] Furthermore, the tests performed after completing one of the first and second sampling operations can overlap in time with the tests performed after completing the other of the first and second sampling operations. That is, both routine blood tests and glycated blood glucose tests can begin after their respective sampling operations are completed. These two tests can run in parallel without interfering with each other during testing. By allowing the routine blood tests and glycated blood glucose tests to overlap in time, the overall efficiency of sample testing can also be improved.

[0138] This application also proposes a sample detection method, which can be applied to the sample detection device described in any of the foregoing embodiments.

[0139] See Figure 10 , Figure 10 This is a flowchart illustrating one embodiment of the sample detection method of this application, as shown below. Figure 10 As shown, the sample detection methods include:

[0140] Step S11: Control the pipette assembly 11 to collect the first sample and the second sample, so that the first sample and the second sample are temporarily stored in the pipette assembly 11 at the same time.

[0141] The first sample was used for glycation testing, and the second sample was used for routine blood tests.

[0142] Step S12: Control the pipette assembly 11 to perform the first and second sample dispensing operations in sequence, or perform the second and first sample dispensing operations in sequence. Before controlling the pipette assembly 11 to perform the first sample dispensing operation, clean the outer wall of the pipette assembly 11 with a glycosylation agent. After controlling the pipette assembly 11 to perform the first sample dispensing operation, clean the outer wall of the pipette assembly 11 with a diluent.

[0143] The first sample dispensing operation is the operation of the pipette assembly 11 dispensing the first sample, and the second sample dispensing operation is the operation of the pipette assembly 11 dispensing the second sample.

[0144] Specifically, the sample detection method may also include the steps performed by the control module 14 as described in any of the preceding embodiments, which will not be repeated here.

[0145] Unlike existing technologies, the sample testing device in this application includes a pipette assembly, a glycation end product (GAP) detection module, a complete blood count (CBC) detection module, and a control module. The control module is used to: control the pipette assembly to collect a first sample and a second sample, so that the first sample and the second sample are simultaneously and temporarily stored in the pipette assembly; wherein the first sample is for GLP detection and the second sample is for CBC detection; control the pipette assembly to perform a first dispensing operation and a second dispensing operation sequentially, or to perform a second dispensing operation and a first dispensing operation sequentially; wherein the first dispensing operation and the second dispensing operation are respectively the operations of the pipette assembly dispensing the first sample and the second sample; before controlling the pipette assembly to perform the first dispensing operation, the pipette assembly is cleaned with a GA lysing agent. Based on the above method, in the same device, the pipette assembly can be controlled to collect a first sample for glycation end product (GEP) testing and a second sample for complete blood count (CBC) testing, respectively. The first and second samples are then sequentially separated. Before the first separation, the pipette assembly is cleaned with a glycation dissolving agent to remove any residual diluent, reducing or eliminating contamination of the first sample. This cleaning step, whether the first separation is performed before or after the second separation, reduces the possibility of high-strength ions from the diluent being carried into the first sample for GEP testing, thus affecting the accuracy of the test. In other words, even when using the same pipette assembly to aspirate and dispense the first and second samples, both GEP and CBC testing can maintain sufficiently high accuracy. This minimizes the possibility of cross-contamination between GEP and GEP testing when performing combined testing in the same device, thereby improving the reliability of sample testing.

[0146] In the description of this application, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., refer to specific features, structures, materials, or characteristics described in connection with that embodiment or example, which are included in at least one embodiment or example of this application. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.

[0147] Furthermore, the terms "first" and "second" are used for descriptive purposes only and should not be construed as indicating or implying relative importance or implicitly specifying the number of technical features indicated. Thus, a feature defined as "first" or "second" may explicitly or implicitly include at least one of that feature. In the description of this application, "multiple" means at least two, such as two, three, etc., unless otherwise explicitly specified.

[0148] Any process or method described in the flowchart or otherwise herein can be understood as representing a module, segment, or portion of code comprising one or more executable instructions for implementing a particular logical function or process, and the scope of the preferred embodiments of this application includes additional implementations in which functions may be performed not in the order shown or discussed, including substantially simultaneously or in reverse order depending on the function involved, as will be understood by those skilled in the art to which embodiments of this application pertain.

[0149] The logic and / or steps represented in the flowchart or otherwise described herein, for example, can be considered as a ordered list of executable instructions for implementing logical functions, and can be embodied in any computer-readable medium for use by, or in conjunction with, an instruction execution system, apparatus, or device (which may be a personal computer, server, network device, or other system that can fetch and execute instructions from, an instruction execution system, apparatus, or device). For the purposes of this specification, "computer-readable medium" can be any means that can contain, store, communicate, propagate, or transmit programs for use by, or in conjunction with, an instruction execution system, apparatus, or device. More specific examples (a non-exhaustive list) of computer-readable media include: an electrical connection having one or more wires (electronic device), a portable computer disk drive (magnetic device), random access memory (RAM), read-only memory (ROM), erasable and editable read-only memory (EPROM or flash memory), fiber optic devices, and portable optical disc read-only memory (CDROM). Alternatively, the computer-readable medium may be paper or other suitable media on which the program can be printed, since the program can be obtained electronically, for example, by optically scanning the paper or other medium, followed by editing, interpreting, or otherwise processing as necessary, and then stored in a computer memory.

[0150] The above description is merely an embodiment of this application and does not limit the patent scope of this application. Any equivalent structural or procedural transformations made using the content of this application's specification and drawings, or direct or indirect applications in other related technical fields, are similarly included within the patent protection scope of this application.

Claims

1. A sample detection device, characterized in that, include: A pipette assembly for aspirating and dispensing samples; A saccharification detection module, wherein the saccharification detection module is used to perform saccharification detection on the sample; A routine blood test module, wherein the routine blood test module is used to perform routine blood tests on the sample; The control module is used for: The pipette assembly is controlled to collect a first sample and a second sample, so that the first sample and the second sample are simultaneously and temporarily stored in the pipette assembly; wherein, the first sample is the sample used for glycation detection, and the second sample is the sample used for routine blood tests; The pipette assembly is controlled to perform a first sample dispensing operation and a second sample dispensing operation in sequence, or to perform a second sample dispensing operation and a first sample dispensing operation in sequence; wherein, the first sample dispensing operation and the second sample dispensing operation are respectively the operations of the pipette assembly dispensing the first sample and the second sample; Before controlling the pipette assembly to perform the first sample dispensing operation, the pipette assembly is cleaned with a glycosylation agent.

2. The sample detection device according to claim 1, characterized in that, The control module is also used for: After controlling the pipette assembly to perform the first sample dispensing operation, the pipette assembly is cleaned with a diluent.

3. The sample detection device according to claim 2, characterized in that, The control module is specifically used for: Before controlling the pipette assembly to perform the first sample dispensing operation, the outer wall of the pipette assembly is cleaned with a glycosylation agent; After controlling the pipette assembly to perform the first sample dispensing operation, the outer wall of the pipette assembly is cleaned with a diluent.

4. The sample detection device according to claim 3, characterized in that, The control module is specifically used for: In response to the pipette assembly sequentially performing the first and second sample dispensing operations, the outer wall of the pipette assembly is cleaned with the glycated hemolysin before the first sample dispensing operation is performed; the outer wall of the pipette assembly is cleaned with the diluent after the first sample dispensing operation is performed and before the second sample dispensing operation is performed; and the inner and outer walls of the pipette assembly are cleaned with the diluent after the second sample dispensing operation is performed.

5. The sample detection device according to claim 3, characterized in that, The control module is specifically used for: In response to the pipette assembly sequentially performing the second sample dispensing operation and the first sample dispensing operation, after controlling the pipette assembly to perform the second sample dispensing operation and before controlling the pipette assembly to perform the first sample dispensing operation, the outer wall of the pipette assembly is cleaned with a glycated hemolysin; and after the pipette assembly performs the first sample dispensing operation, both the inner and outer walls of the pipette assembly are cleaned with a diluent.

6. The sample detection device according to any one of claims 3 to 5, characterized in that, The control module is also configured to perform at least one of the following operations to clean the outer wall of the pipette assembly: The first type: The sample detection device further includes a reaction cell module, and the control module is used to control the movement of the pipette assembly so that the tip of the pipette assembly is below the liquid surface of the glycated hemolysin in the reaction cell module, and the distance between the tip of the pipette assembly below the liquid surface of the glycated hemolysin and the liquid surface of the glycated hemolysin is the first distance; The control module is further configured to control the movement of the pipette assembly, so that the pipette assembly dispenses the first sample into the reaction cell module, and so that the tip of the pipette assembly remains below the liquid surface of the first sample in the reaction cell module during the dispensing of the first sample, wherein the distance between the tip of the pipette assembly below the liquid surface of the first sample and the liquid surface of the first sample is a second distance; wherein the first distance is greater than the second distance; The second type: The sample detection device further includes a cleaning swab, which is used to clean the outer wall of the pipette assembly. The cleaning swab is connected to the common port of the first three-way valve. The first branch port of the first three-way valve is used to receive the glycated hemolysin, and the second branch port of the first three-way valve is used to receive the diluent. The control module is used to control the common port of the first three-way valve to connect with its first branch port, so as to control the cleaning swab to clean the outer wall of the pipette assembly with a glycosylated hemolysin. The control module is also used to control the common port of the first three-way valve to connect with its second branch port, so as to control the cleaning swab to clean the outer wall of the pipette assembly with a diluent.

7. The sample detection device according to any one of claims 3 to 5, characterized in that, The control module is also configured to perform at least one of the following operations: The first method involves controlling the pipette assembly to collect a third sample and perform a third sample separation operation, wherein the third sample separation operation is a separation operation in which the third sample is ejected for glycation detection, and the third sample is a hemolyzed sample. Before and after the third sample dispensing operation, the inner wall of the pipette assembly is cleaned with a glycosylation agent. Wherein, when the inner wall of the pipette assembly is cleaned with a glycated hemolysin, the volume of the glycated hemolysin aspirated by the pipette assembly is the first volume; When the pipette assembly collects the third sample, the volume of the third sample aspirated by the pipette assembly is the second volume; The first volume is larger than the second volume; The second method: the pipette assembly is connected to the common port of the second three-way valve, the first branch port of the second three-way valve is used to receive the glycated hemolysin, and the second branch port of the second three-way valve is used to receive the diluent; The control module is used to control the common port of the second three-way valve to connect with its first branch port, and to clean the inner wall of the pipette assembly using a glycosylated hemolysin; the control module is also used to control the common port of the second three-way valve to connect with its second branch port, and to clean the inner wall of the pipette assembly using a diluent.

8. The sample detection apparatus according to any one of claims 1 to 5, characterized in that, The sample detection device further includes a reaction chamber module; the reaction chamber module includes a common reaction chamber. The control module is used to control the pipette assembly to perform one of the first and second sample dispensing operations in the common reaction tank, and to perform corresponding detection. The control module is also used to control the pipette assembly to perform the first sample dispensing operation and the second sample dispensing operation in the common reaction tank, and to perform corresponding detection. The time period for the glycation assay overlaps at least partially with the time period for the routine blood test.

9. The sample detection device according to any one of claims 1 to 5, characterized in that, The sample detection device further includes a reaction chamber module; the reaction chamber module includes a first reaction chamber and a second reaction chamber. The control module is used to control the pipette assembly to perform the first sample dispensing operation in the first reaction chamber and to perform the corresponding saccharification detection; The control module is also used to control the pipette assembly to perform the second sample dispensing operation in the second reaction chamber and to perform corresponding blood routine tests; The time period for the glycation assay overlaps at least partially with the time period for the routine blood test.

10. A sample detection method, characterized in that, The sample detection method includes: The pipette assembly is controlled to collect a first sample and a second sample, so that the first sample and the second sample are simultaneously and temporarily stored in the pipette assembly; wherein, the first sample is the sample used for glycation detection, and the second sample is the sample used for routine blood tests; The pipette assembly is controlled to perform a first sample dispensing operation and a second sample dispensing operation in sequence, or to perform a second sample dispensing operation and a first sample dispensing operation in sequence; wherein, the first sample dispensing operation and the second sample dispensing operation are respectively the operations of the pipette assembly dispensing the first sample and the second sample; Before controlling the pipette assembly to perform the first sample dispensing operation, the pipette assembly is cleaned with a glycosylation agent.

Images